公开(公告)号：US10413684B2

公开(公告)日：2019-09-17

申请号：US14373572

申请日：2013-01-17

Applicant: Almirall, S.A.

Inventor： Martin Herder ,  Gerhard Ludanek ,  Ingo Mett ,  Joachim Schmidt

IPC: A61M15/00

Abstract: The invention relates to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient, said activating device being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when pressed by the patient. The inhalation device further comprises an advancing mechanism for advancing a counter means each time the inhalation device has been activated by the patient so that a powder dose has been released into the powder channel. The counter means comprises a mechanical index coupled to a locking mechanism blocking the dosage key (5) and/or the activating device and/or the transportation mechanism after a predetermined number of metering cycles after detection of the index. Moreover, the locking mechanism includes a locking lever (7) for positive engagement with the dosage key (5) and/or the activating device and/or the transportation mechanism in the blocked condition. The inhalation device (1) is characterized in that the locking lever includes signaling means integrally formed therewith engaging the index after said predetermined number of metering cycles.

公开(公告)号：US10300072B2

公开(公告)日：2019-05-28

申请号：US15668817

申请日：2017-08-04

Applicant: ALMIRALL, S.A.

Inventor： Jose Aiguade Bosch ,  Silvia Gual Roig ,  Maria Prat Quinones ,  Carlos Puig Duran

IPC: C07D403/12 ,  A61K31/538 ,  C07D413/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/14 ,  A61K31/4178 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4709 ,  A61K45/06 ,  C07D263/58 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  A61K31/4184

Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

公开(公告)号：US10034867B2

公开(公告)日：2018-07-31

申请号：US15599646

申请日：2017-05-19

Applicant: ALMIRALL, S.A.

Inventor： Maria Dolors Fernandez Forner ,  Maria Prat Quinones ,  Maria Antonia Buil Albero

IPC: A61K31/439 ,  A61K31/56 ,  C07D453/02 ,  A61K47/26 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4745

CPC classification number: A61K31/439 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/4745 ,  A61K31/56 ,  A61K45/06 ,  A61K47/26 ,  C07D453/02 ,  Y10S514/826 ,  A61K2300/00

Abstract: Provided is a powder inhaler comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

公开(公告)号：US20180105509A1

公开(公告)日：2018-04-19

申请号：US15567668

申请日：2016-04-20

Applicant: ALMIRALL, S.A.

Inventor： James DUFFY ,  Mark Stuart CHAMBERS ,  Alastair RAE ,  James OSBORNE ,  Isabelle Anne LEMASSON ,  Michael Daniel GOLDSMITH ,  Andrew SHARPE ,  Silvia FONQUERNA POU

IPC: C07D401/12 ,  C07D231/38 ,  C07D249/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  A61P25/02

CPC classification number: C07D401/12 ,  A61P25/02 ,  C07D231/38 ,  C07D249/06 ,  C07D249/14 ,  C07D401/04 ,  C07D401/14 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.

公开(公告)号：US20170189409A1

公开(公告)日：2017-07-06

申请号：US15313722

申请日：2015-05-21

Applicant: Almirall, S.A.

Inventor： Nuria GODESSART MARINA ,  Cristina BALAGUE PELAEZ

IPC: A61K31/53 ,  C07D487/04

CPC classification number: A61K31/53 ,  A61K31/573 ,  A61K45/06 ,  C07B2200/13 ,  C07C309/04 ,  C07C309/30 ,  C07C309/35 ,  C07D487/04

Abstract: The present invention provides a compound, which is an inhibitor of phosphoinositide 3-kinase delta or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment of an immunobullous skin disease mediated by autoantibodies by oral administration.

公开(公告)号：US09687478B2

公开(公告)日：2017-06-27

申请号：US15095036

申请日：2016-04-09

Applicant: ALMIRALL, S.A.

Inventor： Maria Dolors Fernandez Forner ,  Maria Prat Quinones ,  Maria Antonia Buil Albero

IPC: A61K31/439 ,  A61K31/56 ,  A61K31/4745 ,  A61K45/06 ,  C07D453/02 ,  A61K9/00 ,  A61K47/26

CPC classification number: A61K31/439 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/4745 ,  A61K31/56 ,  A61K45/06 ,  A61K47/26 ,  C07D453/02 ,  Y10S514/826 ,  A61K2300/00

Abstract: Provided is an aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

公开(公告)号：US09549934B2

公开(公告)日：2017-01-24

申请号：US14956836

申请日：2015-12-02

Applicant: ALMIRALL, S.A.

Inventor： Jose Aiguade Bosch ,  Silvia Gual Roig ,  Maria Prat Quinones ,  Carlos Puig Duran

IPC: A61K31/58 ,  A61K31/538 ,  C07D403/12 ,  C07D413/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/14 ,  A61K31/4178 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4709 ,  A61K45/06 ,  C07D263/58 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  A61K31/4184

CPC classification number: A61K31/538 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4709 ,  A61K45/06 ,  C07D263/58 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract translation: 本发明涉及具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂双重活性的新化合物，含有它们的药物组合物，其制备方法及其在呼吸治疗中的用途。

公开(公告)号：US09518050B2

公开(公告)日：2016-12-13

申请号：US14653048

申请日：2013-12-17

Applicant: ALMIRALL, S.A.

Inventor： Laia Sole Feu ,  Ines Carranco Moruno ,  Jose Aiguade Bosch ,  Carlos Puig Duran ,  Silvia Fonquerna Pou

IPC: C07D453/04 ,  A61K31/4709 ,  A61K31/475 ,  A61K31/4704 ,  C07D413/12 ,  A61K45/06 ,  A61K47/48 ,  A61K31/13 ,  A61K31/4184 ,  A61K31/439 ,  C07C271/38 ,  C07D453/02 ,  C07D213/75 ,  C07D215/26 ,  C07D401/12 ,  C07D249/18

CPC classification number: C07D453/04 ,  A61K31/13 ,  A61K31/4184 ,  A61K31/439 ,  A61K31/4704 ,  A61K31/4709 ,  A61K31/475 ,  A61K45/06 ,  A61K47/55 ,  C07C271/38 ,  C07C2601/14 ,  C07D213/75 ,  C07D215/26 ,  C07D249/18 ,  C07D401/12 ,  C07D413/12 ,  C07D453/02

Abstract: The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract translation: 本发明涉及具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂双重活性的新化合物，含有它们的药物组合物，其制备方法及其在呼吸治疗中的用途。

公开(公告)号：US20160303108A1

公开(公告)日：2016-10-20

申请号：US15198289

申请日：2016-06-30

Applicant: Almirall, S.A.

Inventor： Sandrine ALLAIN RUIZ ,  Beatriz SEOANE NUNEZ ,  Gonzalo DE MIGUEL SERRA

IPC: A61K31/4704 ,  A61K45/06 ,  A61K31/58 ,  A61K9/00

CPC classification number: A61K31/4704 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/58 ,  A61K45/06

Abstract: The present invention provides a pharmaceutical composition in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a dose equivalent to a metered nominal dose of about 1.25 or about 2.5 micrograms of free base abediterol administered with the Genuair® inhaler. The present invention also provides said pharmaceutical composition for use in the treatment of respiratory disease such as asthma and chronic obstructive pulmonary disease COPD.

Abstract translation: 本发明提供一种用于吸入的干粉形式的药物组合物，其包含与药学上可接受的载体混合的阿地二醇或药学上可接受的盐，其在吸入时提供相当于约1.25或约2.5微克计量名义剂量的剂量 使用Genuair®吸入器给予游离碱抗抑郁药。 本发明还提供了用于治疗呼吸系统疾病如哮喘和慢性阻塞性肺疾病COPD的所述药物组合物。

公开(公告)号：US20160296503A1

公开(公告)日：2016-10-13

申请号：US15095036

申请日：2016-04-09

Applicant: ALMIRALL, S.A.

Inventor： Maria Dolors FERNANDEZ FORNER ,  Maria PRAT QUINONES ,  Maria Antonia BUIL ALBERO

IPC: A61K31/439 ,  A61K45/06 ,  A61K31/56 ,  A61K9/00 ,  A61K47/26

CPC classification number: A61K31/439 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/4745 ,  A61K31/56 ,  A61K45/06 ,  A61K47/26 ,  C07D453/02 ,  Y10S514/826 ,  A61K2300/00

Abstract: Provided is an aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X− is associated with the positive charge of the nitrogen atom and wherein X− is a pharmaceutically acceptable anion of a mono- or polyvalent acid.

Abstract translation: 本发明提供一种气溶胶容器，其包含粉末吸入剂，其包含3（R） - （2-羟基-2,2-二噻吩-2-基乙酰氧基）-1-（3-苯氧基丙基）-1-氮鎓二环[2.2.2]辛烷，其中 阴离子X-与氮原子的正电荷相关，其中X-是单价或多价酸的药学上可接受的阴离子。